Back

Fibulin-3 as a reliable biomarker of fibrosis in obese subjects with Metabolically Dysfunction Associated Steatotic Liver Disease

2026-01-11 gastroenterology Title + abstract only
View on medRxiv
Show abstract

Introduction and ObjectivesMetabolic dysfunction-associated steatotic liver disease (MASLD) affects about one-quarter of adults worldwide, and liver fibrosis is its strongest predictor of liver-related morbidity and mortality. Using combined in-silico screening and clinical validation, we aimed to identify circulating biomarkers associated with fibrosis progression. Fibulin-3 was identified, and its diagnostic performance was evaluated in biopsy-proven MASLD cohorts. Materials and MethodsThe GS...

Predicted journal destinations